Literature DB >> 7543820

Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines.

P Teder1, J Bergh, P Heldin.   

Abstract

We investigated the production of hyaluronan and the presence of hyaluronan receptors in a panel of human lung carcinoma cell lines, consisting of small cell carcinomas (SCLC) and non-small cell carcinomas (non-SCLC). These transformed cell lines produced only minute amounts of hyaluronan, whereas normal lung fibroblasts synthesized high amounts. CD44 molecules (an integral membrane glycoprotein suggested previously to function as a hyaluronan receptor) were differentially expressed on non-SCLC cell lines but essentially not on the SCLC cell lines. In contrast, RHAMM molecules (receptor for hyaluronan-mediated motility) were preferentially expressed on SCLC cells. Although all the lung tumor cell lines expressed various amounts of CD44 and RHAMM, only the SCLC line U-1752 could bind [3H]hyaluronan. The binding sites were saturated with about 19,700 hyaluronan molecules (Mr 1.4 x 10(6)) bound per cell with a Kd of 0.16 x 10(-9) M. CD44 molecules were responsible for the binding activity since Hermes-1 antibodies that block the binding of hyaluronan to CD44 blocked the binding of [3H]hyaluronan to U-1752 cells. 4-Phorbol 12-myristate 13-acetate (PMA) treatment of U-1752 cells both increased the hyaluronan-binding activity in U-1752 cells as well as induced abrogation of cell-cell and cell-matrix interactions. Addition of hyaluronan inhibited the PMA-induced disassembly of the cells. The fact that CD44 molecules are able to bind [3H]hyaluronan only on the SCLC line U-1752 but not on other lung carcinoma cell lines may be of value as a marker for squamous cell carcinoma differentiation. Furthermore, the inhibitory effect of hyaluronan on the PMA-promoted cell disassembly suggest that hyaluronan surrounding squamous cell carcinoma cells may affect their migration and invasiveness.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543820

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Hyaluronate receptors mediating glioma cell migration and proliferation.

Authors:  Y Akiyama; S Jung; B Salhia; S Lee; S Hubbard; M Taylor; T Mainprize; K Akaishi; W van Furth; J T Rutka
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

2.  Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.

Authors:  Zhongyuan Wang; Yanping Wu; Haifeng Wang; Yangqing Zhang; Lin Mei; Xuexun Fang; Xudong Zhang; Fang Zhang; Hongbo Chen; Ying Liu; Yuyang Jiang; Shengnan Sun; Yi Zheng; Na Li; Laiqiang Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

3.  Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.

Authors:  R Casalegno-Garduño; C Meier; A Schmitt; A Spitschak; I Hilgendorf; S Rohde; C Hirt; M Freund; B M Pützer; M Schmitt
Journal:  Clin Dev Immunol       Date:  2012-06-06

4.  Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma.

Authors:  Xiao-Bo Cheng; Norihiro Sato; Shiro Kohi; Atsuhiro Koga; Keiji Hirata
Journal:  J Cancer       Date:  2015-09-03       Impact factor: 4.207

5.  EGF Functionalized Polymer-Coated Gold Nanoparticles Promote EGF Photostability and EGFR Internalization for Photothermal Therapy.

Authors:  Catarina Oliveira Silva; Steffen B Petersen; Catarina Pinto Reis; Patrícia Rijo; Jesús Molpeceres; Ana Sofia Fernandes; Odete Gonçalves; Andreia C Gomes; Isabel Correia; Henrik Vorum; Maria Teresa Neves-Petersen
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

6.  Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction.

Authors:  Y Yamada; N Itano; H Narimatsu; T Kudo; S Hirohashi; A Ochiai; A Niimi; M Ueda; K Kimata
Journal:  Jpn J Cancer Res       Date:  1999-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.